For heart failure or chronic kidney disease, the American Diabetes Association generally recommends SGLT2 inhibitors as first-line agents, with GLP-1 receptor agonists considered for their benefits on atherosclerotic cardiovascular disease, glycemic control, and weight management, or when SGLT2 inhibitors are not appropriate
SGLT-2 mono therapy Merck DPP-4
For instance, if you make lemonade with too much sugar, you can add water to reach the desired flavor
Eli Lillys pending approval, combined with emerging nextgeneration incretin candidates, ensures that the race for leadership in obesity care is far from settled
GLP-1: slows stomach emptying, reduces glucagon and increases satiety (fullness)